health Boehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns
Boehringer Ingelheim releases detailed phase 3 obesity drug data: 16.6% weight loss, significant liver fat reduction, but tolerability issues spark investor sell-off.
